Analytics & Clinic Reporting

Retina Clinic — Dr. Sarah Mitchell · 146 active patients

Total Injections (6m)

312

52 avg/month

+18% vs prior period

Avg T&E Interval

9.4weeks

Target: ≥10 weeks

+1.2wk improvement

Mean VA Gain

+6.2letters

vs baseline visit

ETDRS · 6-month cohort

AI Acceptance Rate

84%

16% physician override

+3% vs prior period

Fluid-Free Rate

61%

89 of 146 active eyes

+4% vs prior period

Active Patients

146

24 discharged this period

+12 new enrolments

Monthly Injection Volume

Total IVT injections per month

Avg T&E Interval Trend

Mean weeks between injections — clinic cohort

VA Outcome Distribution

ETDRS letter change from baseline

AI Recommendation Outcomes

Acceptance vs override rate — 6 months

Outcome by Treatment Cohort

6-month outcomes · Stratified by diagnosis and anti-VEGF agent

146 patients · 6 cohorts

Diagnosis	Agent	N	DAS (baseline)	DAS (current)	Mean VA Gain	Fluid-Free	Avg Interval	Inj/6m	Trend
nAMD	Faricimab	58	71	38	+7.4	69%	10.2 wk	3.1	Improving
nAMD	Aflibercept 8mg	24	68	41	+5.8	58%	9.4 wk	3.4	Improving
nAMD	Bevacizumab	12	62	52	+2.1	42%	6.8 wk	4.8	Stable
DME	Faricimab	31	65	32	+8.9	74%	10.8 wk	2.9	Improving
DME	Aflibercept 2mg	14	63	44	+4.2	57%	8.2 wk	3.9	Improving
BRVO/CRVO	Faricimab	7	74	28	+11.3	86%	12.4 wk	2.4	Improving

Cohort analysis generated by RetinoFlow AI analytics engine · Last updated 15 May 2026 21:11 · Data excludes patients with <3 visits